Sex differences in injection site reactions with human vaccines

Human Vaccines

Volumn 5, Issue 7, 2009, Pages 441-449

  Cook, Ian F ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Adverse reactions; Human vaccines; Immunization; Injection site; Sex differences

Indexed keywords

ANTHRAX VACCINE; BCG VACCINE; BOTULINUM TOXOID; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; MEASLES RUBELLA VACCINE; MEASLES VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; QUADRACEL; RABIES VACCINE; TETANUS TOXOID; TOXOID; UNCLASSIFIED DRUG; VACCINIA VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARM SWELLING; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; HEPATITIS A; HEPATITIS B; HUMAN; IMMOBILIZATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LIPODYSTROPHY; LYMPHADENITIS; MYALGIA; PAIN THRESHOLD; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; UNSPECIFIED SIDE EFFECT;

EID: 70349543998     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.8476     Document Type: Review

References (134)

1. Chen W, Mempal M, Schober W, Behrendt H, Ring J. Gender difference, sex hormones and immediate type hypersensitivity reactions. Allergy 2008; 63:5-7.
2. Lockshin MD. Sex differences in autoimmune disease. Orthop Clin N Am 2006; 37:629-33.
3. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999; 283:1277-8.
4. Klein SL. Hormonal and immunological mechanisms mediating sex differences in parasite infection. Parasite Immunol 2004; 26:247-64.
5. Hurley RW, Adams MCB. Sex, gender and pain: an overview of a complex field. Anesth Analg 2008; 107:309-17.
6. Bernardes SF, Keogh E, Lima ML. Bridging the gap between pain and gender research: a selective literature review. Eur J Pain 2008; 12:427-40.
7. Fillingim PB, Hastie BA, Ness TJ, Glover TL, Campbell CM, Staud R. Sex-related psychological predictors of baseline pain perception and analgesic responses to pentazocine. Biol Psych 2005; 69:97-112.
8. Guyatt GH, Oxman AD, Kunz R, Vist GC, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008; 336:995-8.
9. Abby P, Samb B, Simondon F, Knudsen K, Seck AM, Bennett J, et al. Sex-specific differences in mortality after high-titre measles immunization in rural Senegal. Bull World Health Organ 1994; 72:761-70.
10. Aaby P, Knudson K, Whittle H, Lisse IM, Poulsen A, Sodeman M, et al. Long-term survival after Edmonton-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. J Pediatr 1993; 122:904-8.
11. Benn CS, Aaby P. Sex-differential responses to preventative health interventions. Dan Med Bull 2007; 54:153-4.
12. Cooper WO, Boyce TG, Wright PF, Griffin MR. Do childhood vaccines have non-specific effects on mortality? Bull World Health Organ 2003; 81:821-6.
13. Hull HF. Letter to Editor. Vaccine 2005; 23:1637-8.
14. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008; 26:3551-5.
15. Supplementary information on vaccine safety, Part 2: Background rates of adverse events following immunization. Department of vaccines and biologicals, World Health Organization, Geneva 2000; www.who.int/immunization_safety/publications/gefi/en/-2ok.
16. Bonhoeffer J, Heininger U, Kohl K, Chen PT, Duclos P, Heijbel H, et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 2004; 21:547-50.
17. Sankilampi U, Honkanen PO, Pyhala R, Leinonen M. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Vaccine 1997; 15:1133-7.
18. Cooverji ND, D'Sa JA. Reactions to adsorbed triple vaccine. Ind Pediatr 1975; 875-7.
19. Verschoor PL, Wilschut JT, de Jonge GA, Kostense PJ. Frequent symptoms after DTPP vaccination. Arch Dis Child 1991; 66:1408-12.
20. Hollinger FB, Adam E, Heiberg D, Melnick JL. Response to hepatitis B vaccine in a young adult population In Viral Hepatitis 1981, International Symposium; Szmuness W, Alter AJ, Maynard JE, eds. Franklin Institute Press. Philadelphia 1982; 451-66.
21. Mitchell JR, Whitney FW. The effect of injection speed on the perception of intramuscular injection pain. AAOHNJ 2001; 49:286-92.
22. Kagawa KJ, Chomel BB, Lery L. Rabies and brucellosis immunization states and adverse reactions to rabies vaccines in veterinary students. Comp Immun Microbiol Infect Dis 1992; 15:79-87.
23. Clarke PD, Adams P, Ibanez R, Herzog C. Rate, intensity and duration of local reactions to virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Trav Med Infect Dis 2006; 4:313-8.
24. de Bruyn G, Rossini AJ, Chiu Y-L, Holman D, Elizaga ML, Frey SE, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004; 22:704-13.
25. Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults [Epidemiology and Social]. AIDS 2006; 20:1039-49.
26. Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Rojas M, et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J Infect Dis 1992; 166:139-44.
27. Migasena S, Heppner DG, Kyle DE, Chongsuphajaisiddhi T, Gordon DM, Suntharasamai P, et al. SPf66 malaria vaccine is safe and immunogenic in malaria naïve adults in Thailand. Acta Trop 1997; 67:215-27.
28. Collier LH, Polakoff S, Mortimer J. Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet 1979; 1:1364-8.
29. White WG, Barnes GM, Barker E, Gall D, Knight P, Griffith AH, et al. Reactions to tetanus toxoid. J Hyg 1973; 71:283-97.
30. Bayas JM, Vilella A, Bertran MJ, Vidal J, Batalla S, Asenjo MA, et al. Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary. Epidemiol Infect 2001; 127:451-60.
31. Mark A, Carlsson R-M, Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999; 17:2067-72.
32. Mark A, Christenson B, Granstrom M, Strandell A, Wickbom B, Bottiger M. Immunity and immunization of children against diphtheria in Sweden. Eur J Clin Microbiol Infect Dis 1989; 8:214-9.
33. Middaugh JP. Side effects of diphtheria-tetanus toxoid in adults. Am J Public Health 1979; 69:246-9.
34. Christy C, Pichichero ME, Reed GF, Decker MD, Anderson EL, Rennels MB, et al. Effect of gender, race and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 1995; 96:584-7.
35. Adverse events after vaccination with DTaP in high school students who have previously been vaccinated with D2T5. CCDR 2006; 32:25-8.
36. Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 2009; 27:765-72.
37. Jackson LA, Starkovich P, Dunstan M, Yu O, Nelson J, Dunn J, et al. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination. Pediatrics 2008; 121:645-52.
38. Scheifele DW, Halperin SA, Ochnio JJ, Ferguson AC, Skowronski DM. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheriatetanus-acellular pertussis vaccine. Pediatr Infect Dis J 2005; 24:1059-66.
39. Skowronski DM, Remple UP, Macnabb J, Pielak K, Patrick DN, Halperin SA, et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity and anticipated impact. Pediatrics 2003; 112:453-9.
40. Pichichero M, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria and 5-component pertussis vaccine in adolescents and adults. JAMA 2005; 293:3003-11.
41. Cook IF, Barr I, Hartel G, Pond D, Hampson AW. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2006; 24:2395-402.
42. Nichol KL, Margolis KL, Lind A, Murdoch M, McFadden R, Hauge M, et al. Side effects associated with influenza vaccination in healthy working adults. Arch Intern Med 1996; 156:1546-50.
43. Govaert TME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double-blind placebo controlled trial. BMJ 1993; 307:988-90.
44. Cate TR, Kasel JA, Couch RB, Six HR, Knight V. Clinical trials of bivalent influenza A/New Jersey/76-A/Victoria/75 vaccines in the elderly. J Infect Dis 1977; 136:518-25.
45. Honkanen PO, Keistinen T, Kivela S-L. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996; 156:205-8.
46. Donalisio MR, Ramalheira RM, Cordeiro R. Adverse reactions to influenza vaccine in the elderly, Campinos District SP, 2000. Rev Soc Bras Med Trop 2003; 36:467-71.
47. Beyer WEP, Palache AM, Kerstens R, Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis 1996; 15:65-70.
48. Masurel N, Laufer J. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg 1984; 92:263-76.
49. Smith JWG, Fletcher WB, Wherry PJ. Reactions to injected influenza vaccine. Dev Biol Stan 1975; 28:377-88.
50. Mostow SR, Eickhoff TC, Chelgren GA, Retailliau HF, Castle M. Studies of inactivated influenza virus vaccine in hospital employees: reactogenicity and absenteeism. J Infect Dis 1977; 136:533-8.
51. Phillips CA, Forsyth BR, Christmas WA, Gump DW, Whorton EB, Rogers I, et al. Purified influenza vaccine: clinical and serologic responses to varying doses and different routes of immunization. J Infect Dis 1970; 122:26-32.
52. Jackson LA, Austin G, Chen RT, Stout R, De Stefano F, Gorse GJ, et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001; 19:4703-9.
53. Robb H, Fausone CA, Rudy DR, McArthur S. Side effects from influenza vaccination: differences between returned and random surveys. Mil Med 1996; 161:29-32.
54. Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity and antibody persistence in adults given inactivated influenza virus vaccines-1978. Rev Infect Dis 1983; 5:737-47.
55. Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 186:1121-7.
56. Couch RB, Winokur P, Brady R, Belshe R, Chen WB, Cate TR, et al. Safety and immunogenicity of a high dose trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656-63.
57. Ponka A, Leinonen M. Adverse reactions to polyvalent pneumococcal vaccine. Scand J Infect Dis 1982; 14:67-71.
58. Socan M, Frelih T, Janet E, Petras T, Peternelj B. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine. Vaccine 2004; 22:3087-91.
59. Cook IF, Pond D, Hartel G. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2007; 25:4767-74.
60. Pittman PR, Gibbs PH, Cannon TL, Friedlander AM. Anthrax vaccine: short term safety experience in humans. Vaccine 2002; 20:972-8.
61. Pittman PR. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine 2002; 20:48-50.
62. Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002; 20:1412-20.
63. Wasserman GM, Grabenstein JD, Pittman PR, Rubertone MV, Gibbs PP, Wang LZ, et al. Analysis of adverse events after anthrax immunization in US Army Medical Personnel. J Occup Environ Med 2003; 45:222-33.
64. McNeil MM, Chiang I-S, Wheeling JT, Zhang Y. Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature. Pharmacoepidemiol Drug Safety 2007; 16:259-74.
65. Hoffman K, Costello C, Menich M, Grabenstein JD, Engler RJM. Using a structured medical rote for determining the safety profile of anthrax vaccine for US soldiers in Korea. Vaccine 2003; 21:4399-409.
66. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008; 300:1532-43.
67. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006; 24:5950-9.
68. Seager C, Moriarity J, Ngai A, Staehle O, Nalin DR. Low incidence of adverse experiences after measles or measles-rubella mass revaccination at a college campus. Vaccine 1994; 12:1018-20.
69. Effects of gender on antibody response and adverse events associated with immunization. Pittman PR. www.hivforum.org/publications/ PhillipPittman.pdf.
70. Talbot TR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, et al. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine. JAMA 2004; 292:1205-12.
71. Turnbull FM, McIntyre PB, Achat HM, Wang H, Stapledon R, Gold M, et al. National study of adverse reactions after vaccination with Bacille Calmette-Guerin. Clin Infect Dis 2002; 34:447-53.
72. 1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45.
73. 1 virus-like particle vaccine in pre adolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:201-9.
74. Keogh E. Sex and gender differences in pain: a selective review of biological and psychosocial factors. J Mens Health Gender 2006; 3:236-43.
75. Piira T, Champion GD, Bustos T, Donnelly N, Lui K. Factors associated with infant pain response following an immunization injection. Early Hum Dev 2007; 83:319-26.
76. Robinson ME, Gagnon CM, Riley JL, Price DD. Altering gender role expectations: Effect on pain tolerance, pain threshold and pain ratings. J Pain 2003; 4:284-8.
77. Robinson ME, Riley JL, Myers CD, Papas RK, Wise EA, Waxenberg LB, et al. Gender role expectations of pain: relationship to sex differences in pain. J Pain 2001; 2:251-7.
78. Robinson ME, George SZ, Dannecker EA, Jump RL, Hirsh AT, Gagnon CM, et al. Sex differences in pain anchors revisited: further investigation of "most intense" and common pain events. Eur J Pain 2004; 8:299-306.
79. Pichichero NE. Acellular pertussis vaccines: towards an improved safety profile. Drug Saf 1996; 15:311-24.
80. Galazka A. Diphtheria vaccines and immunization. WHO/UNICEF Satellite meeting on diphtheria control in European countries participating in MECACAR, Ankara, Turkey 1995; www.who.int/vaccines-documents/DocsPDFo5/ 0602170342_001.pdf.
81. Jackson LA, Benson P, Sneller V-P, Butler JC, Thompson RS, Chen RT, et al. Safety of revaccination with pneumococcal polysaccharide vaccines. JAMA 1999; 281:243-8.
82. Jefferson T, Rudin M, Di Pietrantonj C. Adverse events after immunization with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 2004; 4:84-90.
83. Ipp M, Cohen E, Goldbach M, Macarthur C. Pain response to M-M-R vaccination in 4-6 year old children. Can J Clin Pharmacol 2006; 13:296-9.
84. Cook IF, Murtagh J. Ventrogluteal area - a suitable site for intramuscular vaccination of infants and toddlers. Vaccine 2006; 24:2403-8.
85. Cook IF. Evidence based route of administration of vaccines. Hum Vaccin 2008; 4:67-73.
86. 197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65:242-7.
87. Halperin SA, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J 1999; 18:772-9.
88. Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol 2003; 24:376-9.
89. Levine L, Edsall G. Tetanus toxoid-what determines reaction proneness. J Infect Dis 1981; 144:376.
90. Relihan M. Reactions to tetanus toxoid. J Ir Med Assoc 1969; 62:430-4.
91. Jones AE, Melville-Smith M, Watkins J, Seagroatt V, Rice L, Sheffield F. Adverse reactions in adolescents to reinforcing doses of plain and adsorbed tetanus vaccines. J Pub Health 1985; 7:99-106.
92. Levine L, Ibsen J, McComb JA. Adult immunization: preparation and evaluation of combined fluid tetanus and diphtheria toxoids for adult use. Am J Hyg 1961; 73:20-35.
93. Facktor MA, Bernstein RA, Fireman P. Hypersensitivity to tetanus toxoid. J Allerg Clin Immunol 1973; 52:1-12.
94. Ciofi degli Atti ML, Salmaso S, Cotter B, Gallo G, Alfarone G, Pinto A, et al. Reactogenicity and immunogenicity of adult versus paediatric diphtheria and tetanus booster at 6 years of age. Vaccine 2002; 20:74-9.
95. Scheibel I, Tulinius S, Rasch G, Bojlen K, Petersen CB. Immunization of adults against diphtheria with particular reference to dosage and reactions. Acta Pathol Microbiol Immunol Scand 1947; 319-50.
96. Bjorkholm B, Granstrom M, Wahl M, Hedstrom C-E, Hagberg L. Adverse reactions and immunogenicity in adults to regular and increased dosage of diphtheria vaccine. Eur J Clin Microbiol 1987; 6:637-40.
97. James G, Longshore WA, Hendry JL. Diphtheria immunization studies of students in an urban high school. Am J Hyg 1951; 53:178-201.
98. Scheifele DW, Meekison W, Grace M, Barreto L, Carter AO, Mitchell L, et al. Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. Can Med Assos J 1991; 145:641-7.
99. Pappenheimer AM Jr, Edsall G, Lawrence HS, Banton HJ. A study of reactions following administration of crude and purified diphtheria toxoid in an adult population. Am J Hyg 1950; 52:353-70.
100. Simonsen O, Klaerke M, Klaerke A, Bloch AV, Hansen BR, Hald BR, et al. Revaccination of adults against diphtheria II: combined diphtheria and tetanus revaccination with different doses of diphtheria toxoid 20 years after primary vaccination. Acta Path Microbiol Immun Scand 1986; 94:219-25.
101. Scheifele DW, Bjornson G, Halperin SH, Mitchell L, Boraston S. Role of whole-cell pertussis vaccine in severe local reactions to the preschool (fifth) dose of diphtheria-pertussis-tetanus vaccine. Can Med Assoc J 1994; 150:29-35.
102. Liese JG, Stojanov S, Zink TH, Froeschle J, Klepaldo R, Kronwitter A, et al. Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Pediatr Infect Dis J 2001; 20:981-8.
103. Lawrence EM, Edwards KM, Schiffman G, Thompson JM, Vaughn WK, Wright PF. Pneumococcal vaccine in normal children, primary and secondary vaccination. Am J Dis Child 1983; 137:846-50.
104. Rodriguez R, Dyer PD. Safety of pneumococcal revaccination. J Gen Intern Med 1995; 10:511-2.
105. Rigau-Perez JG, Overturf GD, Chan LS, Weiss J, Powers D. Reactions to booster pneumococcal vaccination in patients with sickle cell disease. Pediatr Infect Dis J 1983; 2:199-202.
106. Linnemann CC, First P, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 1986; 146:1554-6.
107. Quiambao BP, Nohynek HM, Kayhty H, Ollgren JP, Gozum LS, Gepanaygo CP, et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine 2007; 25:4470-7.
108. Borgono JM, McLean AA, Vella PP. Vaccination and revaccination with polyvalent pneumococcal polysaccharaide vaccines in adults and toddlers. Proc Soc Exp Biol Med 1978; 157:148-54.
109. Jackson LA, Neuzil KM, Whitney CG, Starkovich P, Dunstan M, Yu O, et al. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2005; 23:3697-703.
110. Wuorimaa T, Kayhty H, Leroy O, Eskola J. Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine 2001; 19:1863-9.
111. Edelman K, Malmstrom K, He Q, Savolainen J, Terho EO, Mertsola J. Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization. Eur J Pediatr 1999; 158:989-94.
112. Mark A, Bjorksen B, Granstrom M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with alumimum-adsorbed and fluid DT vaccines. Vaccine 1995; 13:669-73.
113. Hedenskog S, Bjorksen B, Blennow M, Granstrom G, Granstrom M. Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine. Int Arch Allery Appl Immunol 1989; 89:156-61.
114. Scheifele DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine 2001; 19:4720-6.
115. Ryan EJ, Nilsson L, Kjellman NIM, Gothefors L, Mills KHG. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin Exp Immunol 2000; 121:193-200.
116. Rowe J, Yerkovich ST, Richmond P, Suriyaarachichi D, Fisher E, Feddema L, et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4 to 6 year old children. Infect Immun 2005; 73:8130-5.
117. Poland GA, Borrud A, Jacobson RM, McDermott K, Wollan PC, Brakke D, et al. Determination of deltoid fat pad thickness: implications for needle length in adult immunization. JAMA 1997; 277:1709-11.
118. Cook IF, Williamson M, Pond D. Definition of needle length required for intramuscular deltoid injection in elderly adults: an ultrasonographic study. Vaccine 2006; 24:937-40.
119. Groswasser J, Kahn A, Bouche B, Hanquinet S, Perlmuter N, Hessel L. Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness. Pediatrics 1997; 100:400-2.
120. Cook IF, Murtagh J. Needle length required for intramuscular vaccination of infants and toddlers: an ultrasonographic study. Aust Fam Phys 2002; 3:295-7.
121. Hick JF, Charboneau JW, Brakke DM, Goergen B. Optimun needle length for diphtheriatetanus-pertussis inoculation of infants. Pediatrics 1989; 84:136-7.
122. Chugh K, Chawla D, Aggarwal BB. Optimum needle length for DPT inoculation of Indian infants. Indian J Pediatr 1993; 60:435-40.
123. Lo YS, Lu CC, Chen LY, Huang LY, Jong YJ. Quantative measurement of muscle and subcutaneous fat thickness in newborn by real-time ultrasonography: a useful method for site and depth evaluation in vaccination. Gaoxiong Yi Xue Ke Xue Za Zhi 1992; 8:75-81.
124. Lippert WC, Wall EJ. Optimal intramuscular needle-penetration depth. Pediatrics 2008; 122:556-63.
125. The ISP Guidebook on Immunization. Singhal T, Amdekar YK, Agarwal R, Eds 2009; 125-7.
126. Sardana K, Garg VK, Bhushan P, Pelhan V, Sharma S. DPT vaccine-induced lipoatrophy: an observations study. Int J Dermatol 2007; 46:1050-4.
127. Haas N, Henz BM, Bunikowski R, Keitzer R. Semicircular lipoatrophy in a child with stsyemic lupus erythematosus after subcutaneous injections with methotrexate. Pediatr Dermatol 2002; 19:432-5.
128. Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report - surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell 2006; 30:319-34.
129. Lawrence GL, Boyd I, McIntyre PB, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004. Comm Dis Intell 2005; 29:248-62.
130. Influenza vaccine-associated adverse events: results of passive surveillance, Canada 2001-2002. CCDR 2002; 28:189-96.
131. Canadian National Report on Immunization. CCDR 2006; 32:1-43.
132. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States 1991-2001, MMWR 2003; 52:1-24.
133. Isaacs D, Lawrence G, Boyd I, Ronaldson K, McEwen J. Reporting of adverse vents following immunization in Australia. J Paediatr Child Health 2005; 41:163-6.
134. Feery B. Adverse reactions after small-pox vaccination. Med J Aust 1977; 2:180-3.